摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-(二氟甲氧基)-1H-吲唑-3-羧酸 | 858661-80-0

中文名称
6-(二氟甲氧基)-1H-吲唑-3-羧酸
中文别名
——
英文名称
6-(Difluoromethoxy)-1H-indazole-3-carboxylic acid
英文别名
——
6-(二氟甲氧基)-1H-吲唑-3-羧酸化学式
CAS
858661-80-0
化学式
C9H6F2N2O3
mdl
——
分子量
228.155
InChiKey
WOTMSMCFGIWLNI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    455.2±40.0 °C(Predicted)
  • 密度:
    1.596

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    75.2
  • 氢给体数:
    2
  • 氢受体数:
    6

反应信息

  • 作为产物:
    描述:
    sodium hydroxide盐酸 作用下, 反应 24.0h, 以26%的产率得到6-(二氟甲氧基)-1H-吲唑-3-羧酸
    参考文献:
    名称:
    WO2006/69097
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
    申请人:Schumacher Richard
    公开号:US20070078147A1
    公开(公告)日:2007-04-05
    The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
    本发明一般涉及烟碱乙酰胆碱受体(nACh受体)的配体、nACh受体的激活,以及与缺陷或功能失调的烟碱乙酰胆碱受体相关的疾病状况的治疗,特别是大脑的疾病状况。此外,本发明涉及作为α7 nACh受体亚型的配体的新化合物(例如,吲唑和苯并噻唑),制备这种化合物的方法,含有这种化合物的组合物,以及这些化合物的使用方法。
  • Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
    申请人:Xie Wenge
    公开号:US20050250808A1
    公开(公告)日:2005-11-10
    The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
    本发明一般涉及尼古丁型乙酰胆碱受体(nACh受体)的配体领域,nACh受体的激活,以及与缺陷或功能异常的尼古丁型乙酰胆碱受体相关的疾病状况的治疗,尤其是大脑的治疗。此外,本发明涉及新型化合物(吲唑和苯并噻唑),其作为α7 nACh受体亚型的配体,制备此类化合物的方法,含有此类化合物的组合物,以及使用这些方法。
  • 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
    申请人:Xie Wenge
    公开号:US20050272735A1
    公开(公告)日:2005-12-08
    The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
    本发明通常涉及乙酰胆碱受体配体(nAChR)领域,nAChR的激活以及与缺陷或功能障碍的乙酰胆碱受体相关的疾病状态的治疗,特别是大脑的乙酰胆碱受体。此外,本发明涉及新化合物(吲唑和苯并噻唑),它们作为α7 nAChR亚型的配体,制备这些化合物的方法,含有这些化合物的组合物以及使用这些化合物的方法。
  • Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
    申请人:Xie Wenge
    公开号:US20050176754A1
    公开(公告)日:2005-08-11
    The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
    本发明涉及尼古丁乙酰胆碱受体(nAChR)配体、nAChR的激活以及与缺陷或失灵的尼古丁乙酰胆碱受体相关的疾病情况的治疗,特别是大脑的疾病情况。此外,本发明还涉及新型化合物,例如吲哚、1H-吲唑、1,2-苯并异噁唑和1,2-苯并异硫嗪,它们作为α7 nAChR亚型的配体,制备这些化合物的方法,含有这些化合物的组合物以及其使用方法。
  • Nicotinic alpha-7 receptor ligands and preparation and uses thereof
    申请人:Nguyen Minh Truc
    公开号:US20060167039A1
    公开(公告)日:2006-07-27
    The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
    本发明通常涉及烟碱乙酰胆碱受体(nAChR)配体领域,nAChRs的激活以及与缺陷或功能失调的烟碱乙酰胆碱受体相关的疾病情况的治疗,特别是大脑。此外,本发明涉及作为α7 nAChR亚型配体的新化合物,制备这种化合物的方法,含有这种化合物的组合物以及其使用方法。
查看更多